Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$24.17 USD

24.17
317,753

-0.21 (-0.86%)

Updated May 21, 2024 12:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Vertex (VRTX) Down 6% Since Last Earnings Report?

by Zacks Equity Research

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 133.33% and 1.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia (ACAD) Down 10.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why

by Zacks Equity Research

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 180% and 6.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Verona (VRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' will focus on Verona Pharma's (VRNA) lead pipeline candidate when it reports its fourth-quarter earnings.

Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others

by Zacks Equity Research

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805

by Zacks Equity Research

Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.

Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.

Incyte (INCY) Reports Positive Long-Term Data From HS Study

by Zacks Equity Research

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA

by Zacks Equity Research

Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.

Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.

AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.

Acer (ACER) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.

Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.

Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.